BackExact Sciences Overview

Exact Sciences Total Current Liabilities

Latest total current liabilities for EXAS: $640M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$641.15M
32.73% YoYΔ $158.12M vs prior year quarter

Peer average

Loading

Exact Sciences Total Current Liabilities History

Loading

Exact Sciences vs. peers: Total Current Liabilities Comparison

Loading

Exact Sciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Exact Sciences (EXAS) FAQ

Exact Sciences's total current liabilities stands at $640M as of December 2025. That compares with $480M in the prior-year period — up 32.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Exact Sciences reported $640M in total current liabilities versus $480M a year earlier — a 32.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $480M in the prior-year period — up 32.7% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Exact Sciences's total current liabilities evolved across reporting periods, while the comparison chart places EXAS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Exact Sciences's reading of $640M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.